Schedule 13G ownership disclosure
Y-MABS THERAPEUTICS INC
Common Stock, $0.0001 par value per share · CUSIP: 984241109
Event date: 2025-09-30
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Paradigm BioCapital Advisors LP
Shares: 0.00 · Class: 0.0%
- Paradigm BioCapital Advisors GP LLC
Shares: 0.00 · Class: 0.0%
- Senai Asefaw, M.D.
Shares: 0.00 · Class: 0%
- Paradigm BioCapital International Fund Ltd.
Shares: 0.00 · Class: 0%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001104659-25-112618
- Form type
- SCHEDULE 13G/A
- Filer
- Paradigm Biocapital Advisors LP
- CIK
- CIK 1855655
- Filed
- Nov 14, 2025
- Reporting period
- Sep 30, 2025
- Description
- Schedule 13G beneficial ownership